Citius Pharmaceuticals (CTXR) Competitors $1.37 +0.05 (+3.79%) Closing price 04:00 PM EasternExtended Trading$1.35 -0.02 (-1.46%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR vs. DTIL, INKT, VRCA, PDSB, ELYM, ICCC, ALGS, PRLD, ATNM, and ABVCShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Precision BioSciences (DTIL), MiNK Therapeutics (INKT), Verrica Pharmaceuticals (VRCA), PDS Biotechnology (PDSB), Eliem Therapeutics (ELYM), ImmuCell (ICCC), Aligos Therapeutics (ALGS), Prelude Therapeutics (PRLD), Actinium Pharmaceuticals (ATNM), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. Its Competitors Precision BioSciences MiNK Therapeutics Verrica Pharmaceuticals PDS Biotechnology Eliem Therapeutics ImmuCell Aligos Therapeutics Prelude Therapeutics Actinium Pharmaceuticals ABVC BioPharma Precision BioSciences (NASDAQ:DTIL) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability. Do institutionals and insiders believe in DTIL or CTXR? 38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 4.0% of Precision BioSciences shares are held by company insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation and earnings, DTIL or CTXR? Precision BioSciences has higher revenue and earnings than Citius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecision BioSciences$68.70M0.86$7.17M-$8.81-0.57Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A Is DTIL or CTXR more profitable? Citius Pharmaceuticals has a net margin of 0.00% compared to Precision BioSciences' net margin of -6,205.79%. Citius Pharmaceuticals' return on equity of -60.03% beat Precision BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets Precision BioSciences-6,205.79% -176.47% -69.05% Citius Pharmaceuticals N/A -60.03%-33.83% Which has more volatility and risk, DTIL or CTXR? Precision BioSciences has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Do analysts rate DTIL or CTXR? Precision BioSciences currently has a consensus price target of $47.00, indicating a potential upside of 838.12%. Citius Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 3,768.61%. Given Citius Pharmaceuticals' higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Precision BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to DTIL or CTXR? In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 1 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.87 beat Citius Pharmaceuticals' score of 0.93 indicating that Precision BioSciences is being referred to more favorably in the media. Company Overall Sentiment Precision BioSciences Very Positive Citius Pharmaceuticals Positive SummaryPrecision BioSciences and Citius Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks. Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.30M$2.48B$5.74B$9.78BDividend YieldN/A1.67%4.40%4.04%P/E RatioN/A22.5330.8326.39Price / SalesN/A506.55382.9086.63Price / CashN/A178.3537.7259.11Price / Book0.356.2910.106.62Net Income-$39.14M$32.94M$3.26B$265.42M7 Day Performance11.84%2.27%3.90%3.58%1 Month Performance-17.96%1.06%3.73%0.46%1 Year Performance-90.74%5.65%37.68%19.41% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals3.1273 of 5 stars$1.37+3.8%$53.00+3,768.6%-92.2%$23.30MN/A0.0020DTILPrecision BioSciences4.0821 of 5 stars$4.95+5.1%$47.00+849.5%-49.3%$58.36M$68.70M-0.56200Positive NewsINKTMiNK Therapeutics2.7059 of 5 stars$14.62-1.9%$37.50+156.5%+89.1%$58.33MN/A-5.0830VRCAVerrica Pharmaceuticals4.6506 of 5 stars$6.16+3.4%$80.00+1,198.7%-76.8%$58.21M$7.57M-0.7440Positive NewsPDSBPDS Biotechnology1.8745 of 5 stars$1.24+4.2%$9.00+625.8%-59.4%$57.82MN/A-1.3520ELYMEliem TherapeuticsN/A$1.90+10.5%N/A-58.3%$56.53MN/A-3.589Positive NewsGap UpHigh Trading VolumeICCCImmuCell0.7542 of 5 stars$6.11+0.2%N/A+69.4%$55.16M$27.30M32.1670ALGSAligos Therapeutics4.4794 of 5 stars$8.77+13.9%$50.00+470.1%-17.8%$53.94M$3.94M-0.4490Positive NewsGap DownPRLDPrelude Therapeutics2.8898 of 5 stars$0.94+8.5%$4.00+323.7%-77.7%$53.44M$7M-0.58120ATNMActinium Pharmaceuticals2.3985 of 5 stars$1.71+1.2%$4.50+163.2%-15.6%$53.35MN/A-1.2330ABVCABVC BioPharma0.6471 of 5 stars$3.13-5.2%N/A+314.0%$53.15M$510K-18.4130 Related Companies and Tools Related Companies DTIL Competitors INKT Competitors VRCA Competitors PDSB Competitors ELYM Competitors ICCC Competitors ALGS Competitors PRLD Competitors ATNM Competitors ABVC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTXR) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access